Back

Sacubitril/Valsartan.

26 May 2019 (08:45 - 09:00)
Organised by:
Congress Presentation Part of: Emerging treatment options in HFpEF Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2019

About the speaker

Photo
Professor Scott Solomon

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail
Mineralocorticoid receptor antagonist.
Professor L. Lund (Stockholm, SE)
Slides Video
Presentation thumbnail
sGC stimulators.
Professor B. Pieske (Rostock, DE)
Slides Video
Presentation thumbnail
Interatrial shunt
Professor W. Abraham (Columbus, US)
Slides Video
Presentation thumbnail
SGLT-2 inhibitors.
Professor P. Seferovic (Belgrade, RS)
Slides Video
Presentation thumbnail
Intravenous iron.
Professor S. von Haehling (Goettingen, DE)
Slides Video

Access the full session

Session thumbnail
Emerging treatment options in HFpEF

The Event

Event poster

Heart Failure 2019

26 May 2019 08:45 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of sacubitril valsartan in heart failure compared to renin angiotensin aldosterone system inhibitors: a systematic review and meta analysis of randomised controlled trials
26 August 2022
thumbnail
Congress Session
Managing HFrEF with experts on the spot: there is no success without action!
27 August 2022
thumbnail
Congress Presentation
Safe electrophysiologic profile of the neprilysin-inhibitor sacubitril in combination with different antiarrhythmic drugs
29 August 2022
thumbnail
Congress Presentation
Small reductions in NTproBNP levels in outpatients treated with sacubitril-valsartan reduce hospitalizations and emergency room visits.
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources